swisspartners Ltd. Invests $233,000 in PerkinElmer, Inc. (NYSE:PKI)

swisspartners Ltd. purchased a new stake in PerkinElmer, Inc. (NYSE:PKI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,813 shares of the medical research company’s stock, valued at approximately $233,000.

A number of other institutional investors have also recently added to or reduced their stakes in PKI. Select Equity Group L.P. raised its holdings in PerkinElmer by 11.0% in the fourth quarter. Select Equity Group L.P. now owns 10,326,036 shares of the medical research company’s stock worth $1,481,786,000 after purchasing an additional 1,019,219 shares during the period. BlackRock Inc. increased its holdings in shares of PerkinElmer by 7.6% in the first quarter. BlackRock Inc. now owns 7,904,659 shares of the medical research company’s stock worth $1,014,091,000 after acquiring an additional 556,072 shares in the last quarter. Ceredex Value Advisors LLC raised its position in shares of PerkinElmer by 0.4% during the first quarter. Ceredex Value Advisors LLC now owns 1,251,337 shares of the medical research company’s stock worth $160,534,000 after purchasing an additional 5,287 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of PerkinElmer by 7.5% in the first quarter. The Manufacturers Life Insurance Company now owns 1,163,843 shares of the medical research company’s stock valued at $149,310,000 after buying an additional 81,506 shares during the period. Finally, Norges Bank bought a new stake in shares of PerkinElmer during the fourth quarter worth $142,590,000. 92.74% of the stock is currently owned by institutional investors and hedge funds.

PKI stock traded down $0.11 during trading hours on Friday, reaching $146.00. 3,740 shares of the stock were exchanged, compared to its average volume of 961,229. The firm’s 50-day simple moving average is $137.57. PerkinElmer, Inc. has a 12 month low of $93.23 and a 12 month high of $162.70. The company has a market cap of $16.37 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 0.40 and a beta of 1.12. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.41 and a current ratio of 1.76.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Tuesday, May 4th. The medical research company reported $3.72 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.69. PerkinElmer had a return on equity of 36.60% and a net margin of 24.19%. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. PerkinElmer’s revenue for the quarter was up 100.4% compared to the same quarter last year. Equities analysts expect that PerkinElmer, Inc. will post 9.44 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 6th. Investors of record on Friday, July 16th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.19%. The ex-dividend date is Thursday, July 15th. PerkinElmer’s payout ratio is 3.37%.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Read More: What is a SEC Filing?

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.